SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Jul 31, 2007 -- Cytokinetics, Incorporated (NasdaqGM:CYTK - News) reported revenues from research and development collaborations of $3.2 million for the second quarter of 2007. Net loss for the second quarter of 2007 was $12.6 million, or $0.27 per share. As of June 30, 2007 cash, cash equivalents, restricted cash and marketable securities totaled $161.6 million.
